Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amylin Pharmaceuticals and Takeda Pharmaceutical have voluntarily halted the ongoing Phase 2 study of investigational combination therapy pramlintide/metreleptin for the treatment of obesity.
Subscribe to our email newsletter
Pramlintide acetate is a synthetic analog of the natural hormone amylin, a neurohormone secreted by the pancreas that is known to play a role in the regulation of appetite, food intake and postprandial glucose concentrations.
Amylin and Takeda have suspended clinical activities to investigate a new antibody-related laboratory finding with metreleptin treatment in two patients who participated in a previously completed clinical study of obesity.
However, Amylin confirmed that the suspension of the ongoing Phase 2 study does not affect the company’s lipodystrophy development program investigating the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy.